Effect of sodium oxybate on energy metabolism in narcolepsy

• Conditions: hypersomnieën; 10021112; hypersomnia; narcolepsy; 10013317

• Registration Number: NL-OMON52823
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Patients:
1. Narcolepsy type 1 based on ICSD-3 criteria.
2. >=18 and <40 years of age.
3. Biologically female.
4. White Caucasian descent.
5. Clinical indication for SXB treatment.
6. BMI >= 25 kg/m2

Matched controls:
1. Biologically female.
2. Age- and BMI-match with patient.
3. White Caucasian descent.

Exclusion Criteria

Patients and matched controls:
1. Previous use of SXB.
2. Contraindications for SXB treatment.
3. Sleep-wake disorders other than narcolepsy type 1.
4. Renal, hepatic or endocrine disease.
5. Use of medication known to influence glucose and/or lipid metabolism or
brown adipose tissue activity (e.g. β-adrenergic receptor blockers).
6. Participation in an intensive weight-loss program or vigorous exercise
program during the year before the start of the study.
7. Pregnant during the study days (due to unreliable body composition
measurements on the InBody machine)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The effect of 4 weeks SXB treatment on basal and cold-induced levels of<br /><br>circulating free fatty acids (FFA) in narcolepsy type 1 patients. </p><br>